Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.
圣地亚哥，2024年4月24日 /PRNewswire/ — 处于商业阶段的生物技术公司Heron Therapeutics, Inc.（纳斯达克股票代码：HRTX）今天宣布，该公司将于美国东部时间2024年5月7日星期二上午8点30分举行电话会议和网络直播，公布2024年第一季度财务业绩并讨论最近的业务亮点。
The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 1497932 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at . An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
可以在美国拨打 (646) 307-1963 或拨打 (800) 715-9871 进行电话会议。请向接线员提供密码 1497932 以加入电话会议。电话会议还将通过Heron网站的 “投资者关系” 部分下的网络直播播出，网址为。电话会议和网络直播的档案也将在电话会议结束后的60天内在Heron的网站上公布。
About Heron Therapeutics, Inc.
关于 Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit .
Heron Therapeutics, Inc. 是一家处于商业阶段的生物技术公司，专注于通过开发和商业化改善医疗保健的治疗创新来改善患者的生活。我们先进的科学、专利技术和创新的药物发现和开发方法使我们能够创建和商业化一系列旨在提高急性护理和肿瘤患者的护理标准的产品组合。欲了解更多信息，请访问。
Forward-looking Statements
前瞻性陈述
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
本新闻稿包含1995年《私人证券诉讼改革法》所定义的 “前瞻性陈述”。Heron提醒读者，前瞻性陈述基于管理层截至本新闻稿发布之日的预期和假设，存在某些风险和不确定性，可能导致实际业绩存在重大差异。这些风险和不确定性包括但不限于公司向美国证券交易委员会提交的文件中确定的风险和不确定性。前瞻性陈述仅在规定的日期反映我们的分析，除非法律要求，否则Heron没有义务更新或修改这些陈述。
Investor Relations and Media Contact:
投资者关系和媒体联系人：
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
艾拉·杜阿尔特
执行副总裁、首席财务官
Heron Therapeutics, Inc
[电子邮件保护]
858-251-4400
SOURCE Heron Therapeutics, Inc.
来源 Heron Therapeutics, Inc.